.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Colorcon
Fuji
Julphar
Federal Trade Commission
AstraZeneca
Citi
McKinsey
Deloitte

Generated: November 20, 2017

DrugPatentWatch Database Preview

CRESEMBA Drug Profile

« Back to Dashboard

Which patents cover Cresemba, and what generic Cresemba alternatives are available?

Cresemba is a drug marketed by Astellas and is included in two NDAs. There are two patents protecting this drug.

This drug has twenty-four patent family members in nineteen countries and eight supplementary protection certificates in seven countries.

The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this compound. Additional details are available on the isavuconazonium sulfate profile page.

Summary for CRESEMBA

US Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 2
Drug Prices:see details
DailyMed Link:CRESEMBA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
CRESEMBA
isavuconazonium sulfate
CAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
POWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
CAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
POWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
POWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
CAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
CAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
CAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
CAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
POWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CRESEMBA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,151,182Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives► Subscribe
7,189,858N-phenyl substituted carbamoyloxyalkyl-azolium derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CRESEMBA

Country Document Number Estimated Expiration
South Korea100449797► Subscribe
MexicoPA02004145► Subscribe
Brazil0015254► Subscribe
Japan3787307► Subscribe
Australia2835201► Subscribe
South Africa200203003► Subscribe
European Patent Office1280795► Subscribe
Denmark1280795► Subscribe
Portugal1280795► Subscribe
Canada2388320► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CRESEMBA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90011-0Sweden► SubscribePRODUCT NAME: ISAVUCONAZOLE; REG. NO/DATE: EU/1/15/1036 20151016
C0096France► SubscribePRODUCT NAME: ISAVUCONAZOLE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
15/073Ireland► SubscribePRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
2016000011Germany► SubscribePRODUCT NAME: ISAVUCONAZONIUM ALS ISAVUCONAZONIUM-SULFAT ODER ALS SALZ MIT EINEM ANDEREN PHARMAZEUTISCH VERTRAEGLICHEN ANION, SOWIE HYDRATE ODER SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/15/1036 20151015
939Luxembourg► SubscribePRODUCT NAME: ISAVUCONBAZOLE EN TANT QUE SULFATE D'ISAVUCONAZONIUM OU EN TANT QUE SEL D'ISAVUCONAZONIUM AVEC TOUT AUTRE ANION PHARMACEUTIQUEMENT ACCEPTABLE, OPTIONNELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151019
2014000122Germany► SubscribePRODUCT NAME: SITAGLIPTIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
0791Netherlands► SubscribePRODUCT NAME: ISAVUCONAZOL ALS ISAVUCONAZONIUM SULFAAT OF ALS EEN ISAVUCONAZONIUM ZOUT MET ELK ANDER FARMACEUTISCH AANVAARDBAAR ANION, NAAR KEUZE IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/15/1036 20151019
2016 00002Denmark► SubscribePRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS AN ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REG. NO/DATE: EU/1/15/1036 20151019
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Queensland Health
Merck
Chinese Patent Office
Express Scripts
Johnson and Johnson
Argus Health
US Army
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot